Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Takamizawa, Shigemasa; Shimoi, Tatsunori; Satomi-Tsushita, Natsuko; Yazaki, Satoshi; Okuya, Toshihiro; Kojima, Yoshiyuki; Okuma, Hitomi Sumiyoshi; Nishikawa, Tadaaki; Tanioka, Miki; Sudo, Kazuki; Noguchi, Emi; Yonemori, Kan

doi:10.1186/s12885-021-09112-9

Cited by 8 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the EMBRACE study, NLR was a general prognostic factor in any chemotherapy regimen and also Nakamoto et al [12] reported that NLR was a prognostic factor for patients treated with paclitaxel plus bevacizumab. By contrast, NLR correlated with progression-free survival but did not correlate with OS in patients treated with capecitabine [18]. Neutrophils analyzed by NLR might be affected to a great extent by myelosuppression brought about by chemotherapy.…”

Section: Discussion/conclusionmentioning

confidence: 79%

Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study

et al. 2022

View full text Add to dashboard Cite

Introduction Recently, absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) have been reported to be prognostic and/or predictive factors in breast cancer. However, most of the investigations on the relationship between systemic inflammatory markers and prognosis have been conducted perioperatively, with few studies reporting on patients with metastatic or recurrent breast cancer (MBC). Here, we investigated the role of ALC and NLR as prognostic factors of MBC. Methods This was a retrospective observational study of patients with MBC treated at the University of Tsukuba Hospital between 2013 and 2020. ALC and NLR clinical data were obtained from the patients’ charts. Based on previous reports, the cutoff value of ALC was set at 1500/µL, and that of NLR, at 3. We investigated the prognostic significance of ALC and NLR. Results About 80% of the 243 included patients were hormone receptor-positive, 20% were HER2-positive and 10% were triple-negative. The patients were grouped as follows: 114 (46.9%) and 129 (53.1%) in the high and low ALC groups and 145 (59.7%) and 98 (40.3%) in the high and low NLR groups, respectively. The group with high ALC at diagnosis of MBC showed significantly better prognosis (p = 0.002), and the median overall survival (OS) was 70.9 months, as compared with 40.2 months for the low ALC group. On multivariate analysis, visceral metastasis, subtype and ALC were independent variables for OS; NLR status was not correlated with OS. Conclusions Analysis of real-world data suggests that ALC at diagnosis of MBC is an independent prognostic factor.

show abstract

Section: Discussion/conclusionmentioning

confidence: 79%

Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous results on the role of NLR in different MBC molecular subtypes have been contradictory ( 9 , 24 - 28 ). In our cohort, we found that NLR was associated with a poor prognosis in patients with HER2-positive or TNBC, but not in patients with HR + HER2 − .…”

Section: Discussionmentioning

confidence: 92%

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study

Shao¹,

Li²,

Liu³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background: The presence of a high neutrophil-to-lymphocyte ratio (NLR) has been associated with increased mortality in several malignancies. And the majority of studies on breast cancer (BC) analyzed patients with early-stage. Fewer studies focused on metastatic BC (MBC). De novo stage IV BC with no prior treatment is more suitable for analyzing prognostic factors. Herein, we examined the prognostic value of baseline NLR in de novo stage IV BC patients.Methods: We retrospectively screened the medical records of female patients who were diagnosed with

show abstract

“…Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-tolymphocyte ratio (PLR) have been reported to be associated with higher mortality in several cancer types (5)(6)(7)(8). High absolute lymphocyte count (ALC), PLR and low NLR are predictors of survival in patients with BC treated with eribulin (9)(10)(11)(12). However, the global phase 3 EMBRACE trial suggested that NLR is a general prognostic factor for improved OS, and ALC is an independent predictor of OS, in eribulin-treated patients (10).…”

Section: Introductionmentioning

confidence: 99%

Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio

Shimada,

Fujimoto,

Matsuura

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

Eribulin is widely used to treat metastatic breast cancer (BC). Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with higher mortality in several cancer types. However, the association between BC prognosis and peripheral immune status remains controversial. In the present study, the relative effects of NLR and PLR on survival in patients with metastatic BC were quantified and their clinical prognostic value was evaluated. This retrospective study included 156 patients with metastatic BC who received eribulin monotherapy at Saitama Medical University International Medical Center. Clinicopathological features were examined (peripheral blood findings and biochemical liver and kidney function test results) and univariate and multivariate analyses were conducted of the overall survival (OS). The 156 patients treated with eribulin had a median follow-up duration of 18.3 months. Before eribulin treatment, patients with absolute lymphocyte counts (ALC) >1,500/µl, NLR <3.0, and PLR <150 had significantly longer OS than those with lower ALC, and higher NLR and PLR (median OS, 25.5 vs. 15.5 months; P<0.01; 20.3 vs. 13.6 months, P<0.01; and 29.2 vs. 14.8 months; P<0.001, respectively). Patients with anemia [hemoglobin (Hb) <10 g/dl] or liver dysfunction [albumin-bilirubin (ALBI) grade 2/3] had significantly shorter OS than those without (P<0.001, respectively). Multivariate analysis revealed low ALBI grade (P<0.001), high Hb (P<0.01) and low PLR (P<0.05) as independent factors of longer OS after eribulin administration. Low PLR, anemia and liver dysfunction might be factors associated with prolonged OS in patients with metastatic BC on eribulin therapy, which could be clinically useful, as their evaluation requires neither new equipment nor invasive testing.

show abstract

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Cited by 8 publications

References 34 publications

Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study

Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study

Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio

Contact Info

Product

Resources

About